Palbociclib
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for accurate information.
Palbociclib Product Information
Palbociclib is listed under API and is intended for analytical research, quality control and pharmaceutical reference standard applications. It is associated with Palbociclib. The product is supplied by Clearsynth under CAT No. CS-T-38566.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Palbociclib
CAS No.
571190-30-2
CAT No.
CS-T-38566
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C24H29N7O2
Molecular Weight
447.53
Category
API Family
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for accurate information.
Description
Regulatory Description
Palbociclib is supplied with detailed characterization data compliant with regulatory guideline. Palbociclib can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Palbociclib.
Overview
Palbociclib (also known as compound number ) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
Synonyms
Palbociclib
Application Notes
Palbociclib (also known as compound number ) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.